Abstract
Since its introduction in 1988, the transjugular intrahepatic portosystemic shunt (TIPS) has become an important treatment for the Budd–Chiari syndrome (BCS). It almost completely replaced surgical shunt treatment and reduced the need of liver transplantation to few cases where TIPS treatment failed. The TIPS intervention is always on top of the medical treatment which consists of anticoagulation and specific treatment of an underlying hematological disease. With the advent of transcaval puncture in cases with occluded hepatic veins, TIPS can successfully be implanted in more than 95% of patients with a very low complication rate. With the use of PTFE-covered stents, long-term patency of the shunt is acceptable with revision required in 40% of patients during 2 years of follow-up and a secondary patency rate of almost 100%.
The present clinical practice guidelines of the European Association for the Study of the Liver recommend a stepwise therapeutic algorithm by order of increasing invasiveness beginning with anticoagulation, angioplasty in patients with web-like BCS, TIPS, and finally, liver transplantation. However, medical treatment is ineffective in more than 80–90% of patients. In addition, it may prolong the time of insufficient hepatic blood supply which may result in disease progression. In contrast, the TIPS leads to a rapid and effective drainage of the hepatic and splanchnic vascular beds, thus improving hepatic function and ameliorating portal hypertension. In this regard, early vascular intervention, e.g., TIPS or angioplasty in cases of short BCS, may be favorable in patients with acute and subacute disease. Survival after TIPS is excellent in both, acute and chronic BCS with a 5 and 10-year survival rate of 90% and 80%, respectively. About half of the patients die from their underlying hematological disease. The TIPS compares favorably with surgical shunt treatment and primary liver transplantation. In addition, it does not compromise later liver transplantation, a fact which justifies a strategy which places liver transplantation at the very end.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Janssen HL, Garcia-Pagan JC, Elias E, Mentha G, Hadengue A, Valla DC. Budd-Chiari syndrome: a review by an expert panel. J Hepatol. 2003;38:364–71.
Mitchell MC, Boitnott JK, Kaufman S, Cameron JL, Maddrey WC. Budd-Chiari syndrome: etiology, diagnosis, and management. Medicine (Baltimore). 1982;61:199–218.
Valla D. Primary Budd-Chiari syndrome. J Hepatol. 2009;50:195–203.
EASL. Clinical practice guidelines: vascular diseases of the liver. J Hepatol. 2016;64:179–202.
Bismuth H, Sherlock DJ. Portasystemic shunting versus liver transplantation for the Budd-Chiari syndrome. Ann Surg. 1991;214:581–9.
Wytte CL, Witte MH, Dumont AE, Frist J, Cole WR. Lymph protein in hepatic cirrhosis and experimental hepatic and portal venous hypertension. Ann Surg. 1968;168:567–76.
Henderson JM, Warren WD, Millikan WJ, Galloway JR, Kawasaki S, Stahl RL, Hertzler G. Surgical options, hematologic evaluation, and pathologic changes in Budd-Chiari syndrome. Am J Surg. 1990;159:41–50.
Orloff MJ, et al. Budd-Chiari syndrome revisited: 38 years´ experience with surgical portal decompression. J Gastrointest Surg. 2012;16:286–300.
Darwish Murad S, et al. A prospective follow-up study on 163 patients with Budd-Chiari syndrome: results from the European network for vascular disorders of the liver (EN-vie). J Hepatol. 2007;46:S4.
Darwish Murad S, Plessier A, Hernandez-Guerra M, Fabris F, Eapen CE, Bahr MJ, et al. Etiology, management, and outcome of the Budd-Chiari syndrome. Ann Intern Med. 2009;151:167–75.
Eapen CE, Velissaris D, Heydtmann M, et al. Favourable medium term outcome following hepatic vein recanalisation and/or transjugular intrahepatic portosystemic shunt for Budd Chiari syndrome. Gut. 2006;55:878–84.
Plessier A, Sibert A, Consigny Y, Hakime A, Zappa M, Denninger MH, et al. Aiming at minimal invasiveness as a therapeutic strategy for Budd-Chiari syndrome. Hepatology. 2006;44:1308–16.
Seijo S, Plessier A, Hoekstra J, Dell’Era A, Mandair D, Rifai K, et al. Good long-term outcome of Budd-Chiari syndrome with a step-wise management. Hepatology. 2013;57:1962–8.
Kohli V, Pande GK, Dev V, Reddy KS, Kaul U, Nundy S. Management of hepatic venous outflow obstruction. Lancet. 1993;342:718–22.
Khuroo MS, Al-Suhabani H, Al-Sebayel M, et al. Budd-Chiari syndrome: long-term effect on outcome with transjugular intrahepatic portosystemic shunt. J Gastroenterol Hepatol. 2005;20:1494–502.
Valla D, Hadengue A, El Younsi M, Azar N, Zeitoun G, Boudet M-J, Molas G, et al. Hepatic outflow block caused by short length hepatic vein stenoses. Hepatology. 1997;25:814–9.
Rössle M, et al. The Budd-Chiari syndrome: outcome after treatment with the transjugular intrahepatic portosystemic shunt. Surgery. 2004;135:394–403.
Kappenschneider T. The Budd-Chiari Syndrome: Change in Treatment since 1990. Dissertation, University Hospital Freiburg, Germany, 2010.
Garcia-Pagan JC, et al. TIPS for Budd-Chiari syndrome: long-term results and prognostics factors in 124 patients. Gastroenterology. 2008;135:808–15.
Mukund A, Gamanagatti S. Imaging and interventions in Budd-Chiari syndrome. World J Radiol. 2011;28:69–177.
Kuo PC, Johnson LB, Hastings G, Pais SO, Plotkin JS, Orens JB, Howell CD, et al. Fulminant hepatic failure from the Budd-Chiari syndrome. A bridge to transplantation with transjugular intrahepatic portosystemic shunt. Transplantation. 1996;62:294–6.
Shreshta R, Durham JD, Wachs M, Bilir BM, Kam I, Trouillot T, Everson GT. Use of transjugular intrahepatic portosystemic shunt as a bridge to transplantation in fulminant hepatic failure due to Budd-Chiari syndrome. Am J Gastroenterol. 1997;92:2304–6.
Gandini R, et al. Transjugular intrahepatic portosystemic shunt patency and clinical outcome in patients with Budd-Chiari syndrome: covered versus uncovered stents. Radiology. 2006;241:298–305.
Hernandez-Guerra M, et al. PTFE-covered stents improve TIPS patency in Budd-Chiari syndrome. Hepatology. 2004;40:1197–202.
Zeitoun G, Escolano S, Hadengue A, Azar N, El Younsi M, Mallet A, Boudet M-J, et al. Outcome of Budd-Chiari syndrome: a multivariate analysis of factors related to survival including surgical portosystemic shunting. Hepatology. 1999;30:84–9.
Darwish Murad S, et al. Determinants of survival and the effect of portosystemic shunting in patients with Budd-Chiari syndrome. Hepatology. 2004;39:500–8.
Rautou PE, Moucari R, Escolano S, Cazals-Hatem D, Denie C, Chagneau-Derrode C, et al. Prognostic indices for Budd-Chiari syndrome: valid for clinical studies but insufficient for individual management. Am J Gastroenterol. 2009;104:1140–6.
Fisher NC, McCafferty I, Dolapci M, Wali M, Buckels JAC, Olliff SP, Elias E. Managing Budd-Chiari syndrome: a retrospective review of percutaneous hepatic vein angioplasty and surgical shunting. Gut. 1999;44:568–74.
Maier WL, Waller RM, Sones PJ. Budd-Chiari web treated by percutaneous transluminal angioplasty. Am J Roentgenol. 1981;137:1257–8.
Martin LG, Henderson JM, Millikan WJ Jr, Casarella WJ, Kaufman SL. Angioplasty for long-term treatment of patients with Budd-Chiari syndrome. Am J Roentgenol. 1990;154:1007–10.
Zhang CQ, Fu LN, Xu L, et al. Long-term effect of stent placement in 115 patients with Budd-Chiari syndrome. World J Gastroenterol. 2003;9:2587–91.
Blum U, Rössle M, Haag K, Ochs A, Blum HE, Hauenstein KH, Astinet F, et al. Budd-Chiari syndrome - technical, hemodynamic, and clinical results of treatment with transjugular intrahepatic portosystemic shunt. Radiology. 1995;197:805–11.
Mancuso A, Fung K, Mela M, et al. TIPS for acute and chronic Budd-Chiari syndrome: a single-centre experience. J Hepatol. 2003;38:751–4.
Perello A, Garcia-Pagan JC, Gilabert R, et al. TIPS is a useful long-term derivative therapy for patients with Budd-Chiari syndrome uncontrolled by medical therapy. Hepatology. 2002;35:132–9.
Rössle M. TIPS: 25 years later. J Hepatol. 2013;59:1081–93.
Ryu RK, Durham JD, Krysl J, et al. Role of TIPS as a bridge to hepatic transplantation in Budd-Chiari syndrome. J Vasc Interv Radiol. 1999;10:799–805.
Segev DL, et al. Twenty years of liver transplantation for Budd-Chiari syndrome: a national registry analysis. Liver Transpl. 2007;13:1285–94.
Langlet P, Valla D. Is surgical portosystemic shunt the treatment of choice in Budd-Chiari syndrome? Acta Gastroenterol Belg. 2002;65:155–60.
Bachet JB, Condat B, Hagege H, et al. Long-term portosystemic shunt patency as a determinant of outcome in Budd-Chiari syndrome. J Hepatol. 2007;46:60–8.
Panis Y, Belghiti J, Valla D, et al. Portosystemic shunt in Budd-Chiari syndrome: long-term survival and factors affecting shunt patency in 25 patients in Western countries. Surgery. 1994;115:276–81.
Ahn SS, Yellin A, Sheng FC, Colonna JO, Goldstein LI, Busuttil RW. Selective surgical therapy of the Budd-Chiari syndrome provides superior survivor rates than conservative medical management. J Vasc Surg. 1987;5:28–37.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Rössle, M. (2020). The Transjugular Intrahepatic Portosystemic Shunt (TIPS) for Budd–Chiari Syndrome. In: Qi, X. (eds) Budd-Chiari Syndrome. Springer, Singapore. https://doi.org/10.1007/978-981-32-9232-1_12
Download citation
DOI: https://doi.org/10.1007/978-981-32-9232-1_12
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-32-9231-4
Online ISBN: 978-981-32-9232-1
eBook Packages: MedicineMedicine (R0)